Bnp Paribas Asset Management Holding S.A. Zymeworks Inc. Transaction History

Bnp Paribas Asset Management Holding S.A.

$40.4 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$4.65 - $7.43 $329,303 - $526,177	70,818 Added 4.92%	1,509,037 $9.28 Million
Q2 2022 Aug 04, 2022	BUY	$4.82 - $7.7 $706,448 - $1.13 Million	146,566 Added 11.35%	1,438,219 $7.62 Million
Q1 2022 May 12, 2022	BUY	$6.0 - $16.98 $875,610 - $2.48 Million	145,935 Added 12.74%	1,291,653 $8.46 Million
Q4 2021 Feb 09, 2022	BUY	$15.19 - $29.33 $4.51 Million - $8.71 Million	296,993 Added 34.99%	1,145,718 $18.8 Million
Q3 2021 Nov 08, 2021	BUY	$27.35 - $37.28 $1.69 Million - $2.31 Million	61,941 Added 7.87%	848,725 $24.6 Million
Q2 2021 Aug 05, 2021	BUY	$26.5 - $38.23 $1.41 Million - $2.03 Million	53,227 Added 7.26%	786,784 $27.3 Million
Q1 2021 May 05, 2021	BUY	$29.83 - $56.81 $2.87 Million - $5.47 Million	96,236 Added 15.1%	733,557 $23.2 Million
Q4 2020 Feb 12, 2021	SELL	$39.12 - $54.99 $2.21 Million - $3.11 Million	-56,465 Reduced 8.14%	637,321 $30.1 Million
Q3 2020 Nov 09, 2020	BUY	$29.21 - $46.58 $7.57 Million - $12.1 Million	259,299 Added 59.68%	693,786 $32.3 Million
Q2 2020 Aug 04, 2020	BUY	$33.67 - $40.0 $1.22 Million - $1.45 Million	36,321 Added 9.12%	434,487 $15.7 Million
Q1 2020 May 12, 2020	BUY	$24.28 - $49.8 $2.26 Million - $4.64 Million	93,244 Added 30.58%	398,166 $14.1 Million
Q4 2019 Feb 11, 2020	SELL	$24.84 - $45.46 $3.25 Million - $5.96 Million	-131,017 Reduced 30.05%	304,922 $13.9 Million
Q3 2019 Nov 12, 2019	SELL	$22.78 - $29.08 $458,903 - $585,816	-20,145 Reduced 4.42%	435,939 $10.8 Million
Q2 2019 Aug 02, 2019	BUY	$15.0 - $22.49 $6.84 Million - $10.3 Million	456,084 New	456,084 $10 Million

Others Institutions Holding ZYME

# of Institutions

Shares Held

296K

Call Options Held

Put Options Held

Strategic Wealth Advisors Group, LLC Sacramento, CA

296K
Shares

$4.56 Million
0.08% of portfolio

View Full List

About Zymeworks Inc.

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $949M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

More about ZYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bnp Paribas Asset Management Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Bnp Paribas Asset Management Holding S.A. with notifications on news.

Account